Entering text into the input field will update the search result below

I-Mab stock falls 8% despite FDA orphan drug status for TJ-CD4B for gastric cancer

Mar. 03, 2022 10:17 AM ETI-Mab (IMAB)By: Ravikash, SA News Editor

Human Digestive System Stomach Anatomy

magicmine/iStock via Getty Images

  • The U.S. Food and Drug Administration granted orphan drug designation to I-Mab's (IMAB -8.1%) TJ-CD4B to treat gastric cancer including cancer of gastroesophageal junction.
  • TJ-CD4B is part of I-Mab's bispecific antibody pipeline. The therapy is currently undergoing phase 1

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.